N/A
Manufactured by AbbVie Inc.
11,848 FDA adverse event reports analyzed
Last updated: 2026-04-14
SEVOFLURANE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by AbbVie Inc.. The most commonly reported adverse reactions for SEVOFLURANE include HYPOTENSION, DRUG INTERACTION, CARDIAC ARREST, BRADYCARDIA, DRUG INEFFECTIVE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for SEVOFLURANE.
Out of 7,719 classified reports for SEVOFLURANE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 11,848 FDA FAERS reports that mention SEVOFLURANE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include HYPOTENSION, DRUG INTERACTION, CARDIAC ARREST, BRADYCARDIA, DRUG INEFFECTIVE, HYPERTHERMIA MALIGNANT. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list AbbVie Inc. in connection with SEVOFLURANE. Always verify the specific product and NDC with your pharmacist.